TP53 and prostate cancer: Interestingly, even in the absence of cisplatin, the DU145 prostate cancer cell line, which was refractory to the anti-cancer activities of BIN1 and TP53 when transfected individually, became vulnerable to ectopically expressed TP53 in the DU145 cells retrovirally expressing BIN1 (Figure S1).